Silexion Therapeutics Aktie - SLXN

Professionelle Tools für Privatanleger.

Premium

Current Price

1,1301

Gebot

1,13

Fragen

1,22

Volumen

260.144

1,1127 Tagesbereich 1,19

0,575 52-Wochen-Bereich 41,85

Handelsende

1,18

Handelsbeginn

1,19

Letzte Trade

2149

1.1301

(formt)

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

15.139.924

Finanzvolumen

US$ 298.831

VWAP

1,1487

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion's Groundbreaking Orthotopic Model Data and the Potential Expansion of its Development Plan Position SIL204 as Potential Transformative...

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

March 11, 2025 -- InvestorsHub NewsWire -- via Wall Street Wire -- Final Patient Enrolled in Pivotal Phase 3 Trial Following Highly...

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics approaches a potential key milestone with upcoming orthotopic pancreatic cancer model data, which, if positive, could...

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Grand Cayman, Cayman Islands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the...

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics reported 50% Tumor Reduction in Breakthrough Preclinical Systemic Administration Data; Maxim Group Analyst recently gave...

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-0.0099	-0.868421052632	1.14	1.2	1.1	235860	1.15198307	CS
4	0.0801	7.62857142857	1.05	1.78	0.98	5257743	1.41048092	CS
12	-0.9099	-44.6029411765	2.04	3.45	0.575	15139924	2.05598853	CS
26	-4.0404	-78.1433130258	5.1705	6.489	0.575	9626900	2.43820634	CS
52	-39.9999	-97.2523705325	41.13	41.85	0.575	8270155	2.94933925	CS
156	-39.9999	-97.2523705325	41.13	41.85	0.575	8270155	2.94933925	CS
260	-39.9999	-97.2523705325	41.13	41.85	0.575	8270155	2.94933925	CS

SLXN - Frequently Asked Questions (FAQ)

What is the current Silexion Therapeutics share price?

The current share price of Silexion Therapeutics is US$ 1,1301

What is the 1 year trading range for Silexion Therapeutics share price?

Silexion Therapeutics has traded in the range of US$ 0,575 to US$ 41,85 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
PRTGPortage Biotech Inc	US$ 9,60 (103,82%)	29,92M
LXRXLexicon Pharmaceuticals Inc	US$ 0,5741 (65,16%)	405,29M
DBVTDBV Technologies SA	US$ 6,12 (56,52%)	21,8M
MYSZMy Size Inc	US$ 1,79 (42,06%)	11,89M
LXEHLixiang Education Holding Company Ltd	US$ 17,70 (32,78%)	217,53k
STSSSharps Technology Inc	US$ 0,0421 (-72,43%)	214,43M
MISTMilestone Pharmaceuticals Inc	US$ 0,88 (-60,89%)	33,47M
XTIAXTI Aerospace Inc	US$ 1,23 (-50,00%)	1,82M
LGMKLogicMark Inc	US$ 0,0258 (-49,41%)	161,36M
ICONIcon Energy Corporation	US$ 0,0516 (-48,40%)	27,6M
LXRXLexicon Pharmaceuticals Inc	US$ 0,5741 (65,16%)	405,29M
DMNDamon Inc	US$ 0,0346 (-22,42%)	314,35M
NVDANVIDIA Corporation	US$ 109,67 (-1,58%)	229,88M
STSSSharps Technology Inc	US$ 0,0421 (-72,43%)	214,43M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 9,845 (-7,30%)	200,21M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Silexion Therapeutics Corporation (SLXN) Börsenkurse

Silexion Therapeutics Corporation (SLXN)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

SLXN Neueste Nachrichten

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

$PYPD - PolyPid Hits Major Milestone: Completes Trial Enrollment, Poised for Potential Breakthrough in $10 Billion Surgical Infection Market

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

PESG Market Update: Silexion Therapeutics’ SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

SLXN - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen